Tamar S. Polonsky to Cardiovascular Diseases
This is a "connection" page, showing publications Tamar S. Polonsky has written about Cardiovascular Diseases.
Connection Strength
3.995
-
Menstrual Cycle Irregularity in Adolescence Is Associated With Cardiometabolic Health in Early Adulthood. J Am Heart Assoc. 2023 09 19; 12(18):e029372.
Score: 0.557
-
Highlights in ASCVD Primary Prevention for 2021. J Am Heart Assoc. 2022 07 05; 11(13):e025973.
Score: 0.514
-
Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. J Am Coll Cardiol. 2018 09 11; 72(11):1224-1226.
Score: 0.394
-
Association of Cardiovascular Health With Subclinical Disease and Incident Events: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2017 Mar 20; 6(3).
Score: 0.356
-
CVD screening in low-risk, asymptomatic adults: clinical trials needed. Nat Rev Cardiol. 2012 10; 9(10):599-604.
Score: 0.259
-
The contribution of early nephropathy to cardiovascular risk. Cardiol Clin. 2010 Aug; 28(3):427-36.
Score: 0.225
-
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e026921.
Score: 0.144
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. 2024 Jan 01; 47(1):81-88.
Score: 0.142
-
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2023 11 01; 8(11):1061-1069.
Score: 0.141
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. J Am Heart Assoc. 2023 10 17; 12(20):e030385.
Score: 0.140
-
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. Am Heart J. 2023 10; 264:31-39.
Score: 0.137
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 05 27; 384(21):1981-1990.
Score: 0.119
-
Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trial. Clin Trials. 2021 08; 18(4):449-456.
Score: 0.116
-
Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study. J Am Heart Assoc. 2020 10 20; 9(19):e016871.
Score: 0.114
-
Dietary Cholesterol and Cardiovascular Risk: A Science Advisory From the American Heart Association. Circulation. 2020 01 21; 141(3):e39-e53.
Score: 0.108
-
Trends in Blood Pressure and High-Sensitivity Cardiac Troponin-T With Cardiovascular Disease: The Cardiovascular Health Study. Am J Hypertens. 2019 09 24; 32(10):1013-1020.
Score: 0.106
-
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):3210-3227.
Score: 0.100
-
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 06 18; 139(25):e1144-e1161.
Score: 0.100
-
Obesity and Cardiovascular Risk in Adults With Celiac Disease. J Clin Gastroenterol. 2016 08; 50(7):545-50.
Score: 0.085
-
Coronary artery calcium score. JAMA. 2014 Aug 27; 312(8):837-8.
Score: 0.074
-
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012 Aug 22; 308(8):788-95.
Score: 0.065